Aytu BioPharma Q1 revenue beats expectations

Aytu Biopharma

13/11/2025 21:14

Overview

Aytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectations

Net income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year ago

Adjusted EBITDA beats expectations, reflecting EXXUA launch investments

Outlook

Aytu BioPharma on track to launch EXXUA in Q4 2025 for MDD market

Result Drivers

ADHD PORTFOLIO - Revenue increased 10% excluding last year's rebate, driven by price increases and improved gross-to-nets

PEDIATRIC PORTFOLIO - Revenue decline due to manufacturing delays and reduced marketing emphasis

EXXUA LAUNCH INVESTMENTS - Adjusted EBITDA impacted by investments for EXXUA launch

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$13.89 mln
$12.40 mln (2 Analysts)
Q1 Net Income
$1.97 mln
Q1 Adjusted EBITDA
Beat
-$600,000
-$1.34 mln (2 Analysts)
Q1 Gross Profit
$9.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00, about 74.3% above its November 12 closing price of $2.06

Press Release: ID:nACS5xzx9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)